By Professor Murray David Norris

Preprints

Han JZR; Phimmachanh M; Hastings JF; Leong H; Ng BH; Ni J; Fontaine-Titley A; Cadell AL; O’Donnell YE; Clearwater M; Kamili A; Haber M; Norris M; Timpson P; Trahair TN; Fletcher JI; Fey D; Kolch W; Latham SL; Croucher DR, Inclusion of JNK-independent drugs within multi-agent chemotherapy improves response in relapsed high-risk neuroblastoma, http://dx.doi.org/10.1101/2025.04.26.650760

Kamili A; Hearn BA; Temelkoska I; Solomon J; Wheatley MS; Bui CHT; Atkinson CJ; Elhassadi L-J; Qureshi S; Murray J; Cadiz R; Gifford AJ; Cui L; Crowley L; Lin A; Mayoh C; Wong-Erasmus M; Failes TW; Arndt GM; Haber M; Norris MD; Dolman MEM; Trahair TN; Fletcher JI, Preclinical trial supports dual inhibition of BCL2 and Aurora kinase A for MYCN -amplified high-risk neuroblastoma, http://dx.doi.org/10.64898/2026.09.06.749004

Azfar M; Gao W; Van den Haute C; Xiao L; Karsa M; Pandher R; Ronca E; Bongers A; Karsa A; Spurling D; Guo X; Mayoh C; Burns MR; Verhelst SHL; Norris MD; Haber M; Vangheluwe P; Somers K, The polyamine transporter ATP13A3 mediates DFMO-induced polyamine uptake in neuroblastoma, http://dx.doi.org/10.1101/2024.02.20.581161

Back to profile page